A new cell ther­a­py start­up from an im­munother­a­py pi­o­neer rais­es $175M in KRAS quest

Among the tus­sle in the biotech space to fi­nal­ly “solve” sol­id tu­mors, a qui­et biotech is now tak­ing its shot — and has some VCs and some big-name sci­en­tif­ic prowess from Fred Hutch to back up its ef­forts.

Affi­ni-T Ther­a­peu­tics, apt­ly named for its em­pha­sis on T cell ther­a­py and armed with 57 em­ploy­ees across two lab spaces in Seat­tle and Boston, raised $175 mil­lion Tues­day to spend as the biotech sees fit — which at this point means build­ing up its dis­cov­ery plat­form and push­ing can­di­dates from its pipeline in­to clin­i­cal tri­als. Ac­cord­ing to the CEO, that mon­ey should last the com­pa­ny through De­cem­ber 2024, or about three years.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER